title: Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.
abstract: Our previous studies have demonstrated that platelet FVIII (2bF8) gene therapy can improve hemostasis in hemophilia A mice, even in the presence of inhibitory antibodies, but none of our studies has targeted human cells. Here, we evaluated the feasibility for lentivirus (LV)-mediated human platelet gene therapy of hemophilia A. Human platelet FVIII expression was introduced by 2bF8LV-mediated transduction of human cord blood (hCB) CD34(+) cells followed by xenotransplantation into immunocompromised NSG mice or NSG mice in an FVIII(null) background (NSGF8KO). Platelet FVIII was detected in all recipients that received 2bF8LV-transduced hCB cells as long as human platelet chimerism persisted. All NSGF8KO recipients (n = 7) that received 2bF8LV-transduced hCB cells survived tail clipping if animals had greater than 2% of platelets derived from 2bF8LV-transduced hCB cells, whereas 5 of 7 survived when human platelets were 0.3% to 2%. Whole blood clotting time analysis confirmed that hemostasis was improved in NSGF8KO mice that received 2bF8LV-transduced hCB cells. We demonstrate, for the first time, the feasibility of 2bF8LV gene delivery to human hematopoietic stem cells to introduce FVIII expression in human platelets and that human platelet-derived FVIII can improve hemostasis in hemophilia A.
authors.affiliation: Department of Pediatrics, Medical College of Wisconsin.
authors.forename: Qizhen
authors.initials: Q
authors.lastname: Shi
authors.forename: Erin L
authors.initials: EL
authors.lastname: Kuether
authors.forename: Yingyu
authors.initials: Y
authors.lastname: Chen
authors.forename: Jocelyn A
authors.initials: JA
authors.lastname: Schroeder
authors.forename: Scot A
authors.initials: SA
authors.lastname: Fahs
authors.forename: Robert R
authors.initials: RR
authors.lastname: Montgomery
mesh_terms: D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism; D001792:Blood Platelets / Q000166:cytology / Q000378:metabolism*; D046528:Chimerism; D036101:Cord Blood Stem Cell Transplantation; D005169:Factor VIII / Q000378:metabolism; D005312:Fetal Blood / Q000378:metabolism; D005786:Gene Expression Regulation; D015316:Genetic Therapy; D006467:Hemophilia A / Q000235:genetics* / Q000628:therapy*; D006801:Humans; D007150:Immunohistochemistry; D016086:Lentivirus / Q000235:genetics / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D016513:Mice, SCID; D010641:Phenotype; D034061:Thrombopoiesis
chemical_list: D018952:Antigens, CD34; D005169:Factor VIII